A cancer vaccine based on the marine antimicrobial peptide pardaxin (GE33) for control of bladder-associated tumors

Biomaterials

Volumn 34, Issue 38, 2013, Pages 10151-10159

  Huang, Han Ning ^a   Rajanbabu, Venugopal ^b   Pan, Chieh Yu ^b   Chan, Yi Lin ^c   Wu, Chang Jer ^a   Chen, Jyh Yih ^b  

^a NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^b INSTITUTE OF CELLULAR AND ORGANISMIC BIOLOGY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Antimicrobial peptide; Bladder tumor; Cancer vaccine; Cytokines; MBT 2; Pardaxin

Indexed keywords

ANTIMICROBIAL PEPTIDE; BLADDER TUMOR; CANCER VACCINE; CYTOKINES; MBT-2; PARDAXIN;

CELL MEMBRANES; CYTOTOXICITY; IMMUNIZATION; MAMMALS; NITROGEN OXIDES; T-CELLS; TUMORS; VACCINES;

CYTOLOGY;

CANCER VACCINE; INTERLEUKIN 12; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROUS OXIDE; PARDAXIN; T LYMPHOCYTE RECEPTOR;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CONTROL; CANCER IMMUNIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

MURINAE; MUS;

ANTIMICROBIAL PEPTIDE; BLADDER TUMOR; CANCER VACCINE; CYTOKINES; MBT-2; PARDAXIN;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; FISH VENOMS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MICE; URINARY BLADDER NEOPLASMS;

EID: 84885370518     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.041     Document Type: Article

References (46)

1. Rajanbabu V., Chen J.Y. The antimicrobial peptide, tilapia hepcidin 2-3, and PMA differentially regulate the protein kinase C isoforms, TNF-alpha and COX-2, in mouse RAW264.7 macrophages. Peptides 2011, 32:333-341.
2. Huang H.N., Pan C.Y., Rajanbabu V., Chan Y.L., Wu C.J., Chen J.Y. Modulation of immune responses by the antimicrobial peptide, epinecidin (Epi)-1, and establishment of an Epi-1-based inactivated vaccine. Biomaterials 2011, 32:3627-3636.
3. Primor N., Tu A.T. Conformation of pardaxin, the toxin of the flatfish Pardachirus marmoratus. Biochim Biophys Acta 1980, 626:299-306.
4. Oren Z., Shai Y. Aclass of highly potent antibacterial peptides derived from pardaxin, a pore-forming peptide isolated from Moses sole fish Pardachirus marmoratus. Eur J Biochem 1996, 237:303-310.
5. Oren Z., Hong J., Shai Y. Arepertoire of novel antibacterial diastereomeric peptides with selective cytolytic activity. JBiol Chem 1997, 272:14643-14649.
6. Abu-Raya S., Bloch-Shilderman E., Shohami E., Trembovler V., Shai Y., Weidenfeld J., et al. Pardaxin, a new pharmacological tool to stimulate thearachidonic acid cascade in PC12 cells. JPharmacol Exp Ther 1998, 287:889-896.
7. Abu-Raya S., Bloch-Shilderman E., Lelkes P.I., Trembovler V., Shohami E., Gutman Y., et al. Characterization of pardaxin-induced dopamine release from pheochromocytoma cells: role of calcium and eicosanoids. JPharmacol Exp Ther 1999, 288:399-406.
8. Bloch-Shilderman E., Jiang H., Abu-Raya S., Linial M., Lazarovici P. Involvement of extracellular signal-regulated kinase (ERK) in pardaxin-induced dopamine release from PC12 cells. JPharmacol Exp Ther 2001, 296:704-711.
9. Hsu J.C., Lin L.C., Tzen J.T., Chen J.Y. Pardaxin-induced apoptosis enhances antitumor activity in HeLa cells. Peptides 2011, 32:1110-1116.
10. Huang T.C., Lee J.F., Chen J.Y. Pardaxin, an antimicrobial peptide, triggers caspase-dependent and ROS-mediated apoptosis in HT-1080 cells. Mar Drugs 2011, 9:1995-2009.
11. Wu S.P., Huang T.C., Lin C.C., Hui C.F., Lin C.H., Chen J.Y. Pardaxin, a fish antimicrobial peptide, exhibits antitumor activity toward murine fibrosarcoma invitro and invivo. Mar Drugs 2012, 10:1852-1872.
12. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
13. Caffo O., Veccia A., Fellin G., Russo L., Mussari S., Galligioni E. Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature. Crit Rev Oncol Hematol 2013, 86:176-190.
14. Sadick M., Schoenberg S.O., Hoermann K., Sadick H. Current oncologic concepts and emerging techniques for imaging of head and neck squamous cell cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg 2012, 11. Doc08.
15. Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. JAmino Acids 2012, 2012. 967347.
16. Aina O.H., Sroka T.C., Chen M.L., Lam K.S. Therapeutic cancer targeting peptides. Biopolymers 2002, 66:184-199.
17. Morcos E., Jansson O.T., Adolfsson J., Kratz G., Wiklund N.P. Endogenously formed nitric oxide modulates cell growth in bladder cancer cell lines. Urology 1999, 53:1252-1257.
18. Brayer J.B., Pinilla-Ibarz J. Developing strategies in the immunotherapy of leukemias. Cancer Control 2013, 20:49-59.
19. Iida N., Nakamoto Y., Baba T., Kakinoki K., Li Y.Y., Wu Y., et al. Tumor cell apoptosis induces tumor-specific immunity in a CC chemokine receptor 1- and 5-dependent manner in mice. JLeukoc Biol 2008, 84:1001-1010.
20. Kurtz S.L., Foreman O., Bosio C.M., Anver M.R., Elkins K.L. Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection. Infect Immun 2013, 81:585-597.
21. Ni J., Miller M., Stojanovic A., Garbi N., Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. JExp Med 2012, 209:2351-2365.
22. Bellmann-Weiler R., Schroll A., Engl S., Nairz M., Talasz H., Seifert M., et al. Neutrophil gelatinase-associated lipocalin and interleukin-10 regulate intramacrophage Chlamydia pneumoniae replication by modulating intracellular iron homeostasis. Immunobiology 2013, 218:969-978.
23. Vendramini-Costa D.B., Carvalho J.E. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 2012, 18:3831-3852.
24. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
25. Gregory A.D., Houghton A.M. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011, 71:2411-2416.
26. Tanikawa T., Wilke C.M., Kryczek I., Chen G.Y., Kao J., Nunez G., et al. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res 2012, 72:420-429.
27. Knutson K.L., Disis M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005, 54:721-728.
28. Fruh K., Yang Y. Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol 1999, 11:76-81.
29. Gao F.G., Khammanivong V., Liu W.J., Leggatt G.R., Frazer I.H., Fernando G.J. Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res 2002, 62:6438-6441.
30. Terme M., Fridman W.H., Tartour E. NK cells from pleural effusions are potent antitumor effector cells. Eur J Immunol 2013, 43:331-334.
31. Kipriyanov S.M., Cochlovius B., Schafer H.J., Moldenhauer G., Bahre A., Le Gall F., et al. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. JImmunol 2002, 169:137-144.
32. Zhao J., Gao Z., Tian Z., Xie Y., Xin F., Jiang R., et al. The biological effects of individual-level PM2.5 exposure on systemic immunity and inflammatory response in traffic policemen. Occup Environ Med 2013, 70:426-431.
33. Iero M., Filipazzi P., Castelli C., Belli F., Valdagni R., Parmiani G., et al. Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?. Cancer Immunol Immunother 2009, 58:1159-1167.
34. Soloway M.S. Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 1977, 37:2918-2929.
35. Rajanbabu V., Pan C.Y., Lee S.C., Lin W.J., Lin C.C., Li C.L., et al. Tilapia hepcidin 2-3 peptide modulates lipopolysaccharide-induced cytokines and inhibits tumor necrosis factor-alpha through cyclooxygenase-2 and phosphodiesterase 4D. JBiol Chem 2010, 285:30577-30586.
36. Amano F., Noda T. Improved detection of nitric oxide radical (NO.) production in an activated macrophage culture with a radical scavenger, carboxy PTIO and Griess reagent. FEBS Lett 1995, 368:425-428.
37. Jiang F., Zhou X.M. Amodel of orthotopic murine bladder (MBT-2) tumor implants. Urol Res 1997, 25:179-182.
38. Hikosaka S., Hara I., Miyake H., Hara S., Kamidono S. Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model. Int J Urol 2004, 11:647-652.
39. Chen S.A., Tsai M.H., Wu F.T., Hsiang A., Chen Y.L., Lei H.Y., et al. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine. Clin Cancer Res 2000, 6:4381-4388.
40. Chou B., Hiromatsu K., Okano S., Ishii K., Duan X., Sakai T., et al. Antiangiogenic tumor therapy by DNA vaccine inducing aquaporin-1-specific CTL based on ubiquitin-proteasome system in mice. JImmunol 2012, 189:1618-1626.
41. Ding G.Q., Yu Y.L., Shen Z.J., Zhou X.L., Chen S.W., Liao G.D., et al. Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Guerin vaccine on bladder cancer cells. JZhejiang Univ Sci B 2012, 13:335-341.
42. Fox J.L. Antimicrobial peptides stage a comeback. Nat Biotechnol 2013, 31:379-382.
43. Bhunia A., Domadia P.N., Torres J., Hallock K.J., Ramamoorthy A., Bhattacharjya S. NMR structure of pardaxin, a pore-forming antimicrobial peptide, in lipopolysaccharide micelles: mechanism of outer membrane permeabilization. JBiol Chem 2010, 285:3883-3895.
44. Vacchelli E., Martins I., Eggermont A., Fridman W.H., Galon J., Sautes-Fridman C., et al. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2012, 1:1557-1576.
45. Buonaguro L., Petrizzo A., Tornesello M.L., Buonaguro F.M. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011, 18:23-34.
46. Huang T.C., Chen J.Y. Proteomic analysis reveals that pardaxin triggers apoptotic signaling pathways in human cervical carcinoma HeLa cells: crosstalk among the UPR, c-Jun, and ROS. Carcinogenesis 2013, 34:1833-1842.